Toxoplasma gondii</italic> is an obligate intracellular, protozoan parasite of the phylum Apicomplexa. While the parasite relies on the feline to complete its life-cycle, many mammals can contract the infection. In humans, infection can cause serious illness or death. Treatments currently available are limited by toxicity and teratogenicity. This necessitates the development of novel drug compounds. Tryptanthrin and its analogue, 8-bromotryptanthrin, have shown promise in the treatment of <italic>Toxoplasma gondii in vitro</italic>. New tryptanthrin derivatives were synthesized, characterized, and tested for efficacy and toxicity. These compounds show a structure-activity relationship at the 8-position and low toxicity.
University of Minnesota M.S. thesis. April 2013. Major: Chemistry. Advisor: Peter Grundt. 1 computer file (PDF); vi, 133 pages, appendix I.
Czerniecki, Nikolas Johann.
Development and characterization of novel toxoplasma gondii inhibitors.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.